Virpax Pharmaceuticals In... (VRPX)
| Bid | 0.49 |
| Market Cap | 622.49K |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -71 |
| PE Ratio (ttm) | -0.01 |
| Forward PE | -0.31 |
| Analyst | n/a |
| Ask | 0.5 |
| Volume | 1,618,674 |
| Avg. Volume (20D) | 364,196 |
| Open | 1.18 |
| Previous Close | 1.22 |
| Day's Range | 0.48 - 1.18 |
| 52-Week Range | 0.48 - 104.28 |
| Beta | 0.96 |
About VRPX
Virpax Pharmaceuticals, Inc., a preclinical-stage pharmaceutical company, develops various drug-delivery systems and drug-releasing technologies focused on advancing non-opioid and non-addictive pain management treatments and treatments for central nervous system disorders. Its preclinical stage product candidates include Epoladerm, a topical nonsteroidal anti-inflammatory drug treatment for chronic osteoarthritis of the knee; Probudur, an inject...
4 weeks ago · businesswire.com
Virpax's NES100 to be Presented at The Society of Toxicology by NCATSBERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic s...
2 months ago · businesswire.com
Virpax's Matthew Barnes to Present at Outsourcing in Clinical Trials ConferenceBERWYN, Pa.--(BUSINESS WIRE)--Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”), a company specializing in developing non-addictive products for pain management, post-traumatic s...
